Harmony Biosciences (HRMY) Tops Q3 EPS by 22c

Harmony Biosciences (NASDAQ: HRMY) reported Q3 EPS of $0.51, $0.22 better than the analyst estimate of $0.29. Revenue for the quarter came in at $80.7 million versus the consensus estimate of $80.92 million.

For earnings history and earnings-related data on Harmony Biosciences (HRMY) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• BIG3 Basketball to go public via Graf Global merger at $290 million
• Harmony Biosciences Announces Poster Presentations at 2026 SLEEP Annual Meeting